Analyzing...
Loading company...
Gujarat Themis Biosyn Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Mumbai, Maharashtra and currently employs 109 full-time employees. Gujarat Themis Biosyn Limited is an India-based company, which is principally engaged in the manufacturing of pharmaceuticals and medicinal chemical products. The firm is focused on the business of manufacturing and sale of finished active pharmaceutical ingredients (API) products by fermentation process. The firm operates through manufacturing of the bulk drugs segment. Its product portfolio comprises Rifamycin-O and Rifamycin-S. The firm is manufacturing Rifamycin S, which is an intermediate for manufacturing the drug Rifampicin (an Antibiotic used for the treatment of several types of bacterial infections, including tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease.) and Rifamycin O, which is an intermediate for manufacturing the drug Rifaximin (this is an Antibiotic used for treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy). Its research and development division focuses on developing fermentation cultures.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹166 Cr revenue.
COGS 12.9%, employees 10.0%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 16.2%▲ | 10.3% |
| ROCE | 15.3%▲ | 13.7% |
| Net Margin | 27.8%▲ | 7.6% |
| EBITDA Margin | 46.3%▲ | 15.4% |
| Debt To Equity | 0.56x▲ | 0.15x |
Historical valuation data not available.
Revenue segment breakdown not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹166 Cr +10.0% | ₹151 Cr -11.2% | ₹170 Cr +14.0% | ₹149 Cr +29.7% | ₹115 Cr +26.8% | ₹91 Cr +6.4% | ₹85 Cr +107.4% | ₹41 Cr |
| Other Income | ₹2 Cr -0.2% | ₹2 Cr -44.3% | ₹4 Cr -27.5% | ₹6 Cr +48.7% | ₹4 Cr +24.0% | ₹3 Cr +91.7% | ₹2 Cr -23.0% | ₹2 Cr |
| Total Income | ₹168 Cr +9.8% | ₹153 Cr -12.0% | ₹174 Cr +12.4% | ₹155 Cr +30.4% | ₹119 Cr +26.7% | ₹94 Cr +8.1% | ₹87 Cr +100.7% | ₹43 Cr |
| COGS | ₹21 Cr -12.7% | ₹25 Cr -33.2% | ₹37 Cr +38.4% | ₹26 Cr +59.5% | ₹17 Cr +8.1% | ₹15 Cr +35.6% | ₹11 Cr +768.9% | ₹1 Cr |
| ₹106 Cr +21.1% | ₹88 Cr -7.5% | ₹95 Cr +22.3% | ₹78 Cr +29.5% | ₹60 Cr +13.1% | ₹53 Cr -4.7% | ₹56 Cr +58.5% | ₹35 Cr | |
| Profit Before Tax | ₹62 Cr -5.3% | ₹66 Cr -17.4% | ₹79 Cr +2.4% | ₹77 Cr +31.2% | ₹59 Cr +44.4% | ₹41 Cr +30.8% | ₹31 Cr +281.4% | ₹8 Cr |
| ₹15 Cr -8.1% | ₹17 Cr -16.9% | ₹20 Cr +3.5% | ₹19 Cr +26.5% | ₹15 Cr +44.0% | ₹11 Cr +41.2% | ₹8 Cr +324.4% | ₹2 Cr | |
| Net Profit | ₹47 Cr -4.3% | ₹49 Cr -17.6% | ₹59 Cr +2.1% | ₹58 Cr +32.9% | ₹44 Cr +44.5% | ₹30 Cr +27.5% | ₹24 Cr +269.4% | ₹6 Cr |
| Other Comprehensive Income | ₹0.01 Cr -90.2% | ₹0.05 Cr ↑ Recovery | (₹0.03 Cr) ↓ Decline | ₹0.06 Cr ↑ Recovery | (₹0.08 Cr) -159.9% | (₹0.03 Cr) ↓ Decline | ₹0.00 Cr -16.7% | ₹0.00 Cr |
| EPS | ₹4.28 | ₹4.48 | ₹5.43 | ₹5.32 | ₹4.00 | ₹2.77 | ₹2.17 | ₹0.59 |
| Diluted Shares | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
No earnings call transcripts available.
Gujarat Themis Biosyn Limited has informed the Exchange about Copy of Newspaper Publication
Gujarat Themis Biosyn Limited has informed the Exchange regarding Notice of Extraordinary General Meeting to be held on August 22, 2026
CTL Trusteeship Ltd has submitted to the Exchange a copy of Disclosure under Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulatio...
Gujarat Themis Biosyn Limited has informed the Exchange about Copy of Newspaper Publication for Postal Ballot.
Gujarat Themis Biosyn Limited has informed the Exchange regarding Notice of Postal Ballot dated 22.07.2026
Gujarat Themis Biosyn Limited has informed the Exchange about Credit Rating- Revision
Gujarat Themis Biosyn Limited has informed the Exchange about Credit Rating- Revision
Sachin D. Patel has Submitted to the Exchange a copy of Disclosure under Regulation 10 (5) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, ...
PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED has submitted to the Exchange a copy of Disclosure under Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
Gujarat Themis Biosyn Limited has informed the Exchange about General Updates on Arbitration matter.
Gujarat Themis Biosyn Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot
Gujarat Themis Biosyn Limited has informed the Exchange regarding Proceedings of Postal Ballot. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.
Gujarat Themis Biosyn Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Gujarat Themis Biosyn Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot
Gujarat Themis Biosyn Limited has informed the Exchange regarding Proceedings of Postal Ballot. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.